Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells: Role of c-Jun, c-Fos, and Fra-1 in cell cycle regulation

Molecular and Cellular Biochemistry

Volumn 380, Issue 1-2, 2013, Pages 143-151

  Babu, R L ^a   Naveen Kumar, M ^a   Patil, Rajeshwari H ^a   Devaraju, K S ^a   Ramesh, Govindarajan T ^b   Sharma, S Chidananda ^a  

^a BANGALORE UNIVERSITY   (India)

^b NORFOLK STATE UNIVERSITY   (United States)

Author keywords

AP 1; Estrogen; MCF 7; MTT; qRT PCR; Tamoxifen

Indexed keywords

CYCLIN D1; CYCLIN E1; CYCLINE; ESTRADIOL; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN C JUN; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUND; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; CYCLIN E; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAMOXIFEN; TRANSCRIPTION FACTOR AP-1;

MAMMALIA;

EID: 84879799393     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1667-x     Document Type: Article

References (50)

1. Yang SH, Liu R, Perez EJ, Wen Y, Stevens SM Jr, Valencia T, Brun-Zinkernagel AM, Prokai L, Will Y, Dykens J, Koulen P, Simpkins JW (2004) Mitochondrial localization of estrogen receptor. Proc Natl Acad Sci 101:4130-4135
2. Osborne CK, Zhao H, Suzanne A, Fuqua W (2000) Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 18:3172-3186
3. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P (2000) Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311-317
4. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA, Safe S (2000) Ligand, cell, and estrogen receptor subtype (alpha/beta)- dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275:5379-5387
5. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH (2002) Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 21:7680-7689
6. Eferl R, Wagner EF (2003) AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3:859-868
7. Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4:E131-E136
8. Shaulian E (2010) AP-1 - the Jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal 22:894-899
9. Sharma SC, Richards JS (2000) Regulation of AP1 (Jun/Fos) factor expression and activation in ovarian granulosa cells. Relation of JunD and Fra2 to terminal differentiation. J Biol Chem 275:33718-33728
10. Karin M (1995) The Regulation of AP-1 Activity by mitogen-activated protein kinases. J Biol Chem 270:16483-16486
11. Carlone DL, Richards JS (1997) Functional interactions, phosphorylation, and levels of 3′,5′-cyclic adenosine monophosphate-regulatory element binding protein and steroidogenic factor-1 mediate hormone-regulated and constitutive expression of aromatase in gonadal cells. Mol Endocrinol 11:292-304
12. Chinenov Y, Kerppola TK (2001) Close encounters of many kinds: fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 20:2438-2452
13. Pei L, Dodson R, Schoderbek WE, Maurer RA, Mayo KE (1991) Regulation of the alpha inhibin gene by cyclic adenosine 3′,5′-monophosphate after transfection into rat granulosa cells. Mol Endocrinol 5:521-534
14. Mukherjee A, Park-Sarge OK, Mayo KE (1996) Gonadotropins induce rapid phosphorylation of the 3′,5′-cyclic adenosine monophosphate response element binding protein in ovarian granulosa cells. Endocrinology 137:3234-3245
15. Herdegen T, Leah JD (1998) Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Rev 28:370-490
16. Milde-Langosch K, Kappes H, Riethdorf S, Loning T, Bamberger AM (2003) FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas. Breast Cancer Res Treat 77:265-275
17. Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH (2004) AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene 23:8238-8246
18. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ (1999) cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18:6063-6070
19. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH (2008) The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 27:366-377
20. Periyakaruppan A, Kumar F, Sarkar S, Sharma SC, Ramesh GT (2007) Uranium induces oxidative stress in lung epithelial cells. Arch Toxicol 81:389-395
21. Sharma SC, Clemens JW, Pisarska MD, Richards JS (1999) Expression and function of estrogen receptor subtypes in granulosa cells: regulation by estradiol and forskolin. Endocrinology. 140:4320-4334
22. Bernard K, Cambiaggi A, Guia S, Bertucci F, Granjeaud S, Tagett R, Guyen CN, B Jordan BR, Vivier ENK (1999) Cell Line Regulates AP-1 Expression in the NKL Human Engagement of Natural Cytotoxicity Programs. J Immunol 162:4062-4068
23. Bundred NJ (2001) Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27:137-142
24. Huber C, Bouchardy C, Schaffar R, Neyroud-Caspar I, Vlastos G, Le Gal FA, Rapiti E, Benhamou S (2012) Antiestrogen Therapy for Breast Cancer Modifies the Risk of Subsequent Cutaneous Melanoma. Cancer Prev Res 5:82-88
25. Egawa C, Miyoshi Y, Iwao K, Shiba E, Noguchi S (2001) Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction. Oncology 61:293-298
26. Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537-2541
27. Oosterkamp HM, Bernards R (2004) Androgen receptors and estrogen receptors. La Thangue, N.B, Bandara, L.R (ed) Targets of cancer chemotherapy: Transcription factors and other nuclear protiens. Human Press., Totowa, NJ pp 315-331
28. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467
29. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P (2000) Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311-317
30. Miner JN, Diamond MI, Yamamoto KR (1991) Joints in the regulatory lattice: composite regulation by steroid receptor-AP1 complexes. Cell Growth Differ 2:525-530
31. Pfahl M (1993) Nuclear receptor/AP-1 interaction. Endocr Rev 14:651-658
32. Ponta H, Cato AC, Herrlich P (1992) Interference of pathway specific transcription factors. Biochim Biophys Acta 1129:255-261
33. Philips A, Chalbos D, Rochefort H (1993) Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 268:14103-14108
34. Webb P, Lopez GN, Uht RM, Kushner PJ (1995) Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443-456
35. Yang-Yen HF, Zhang XK, Graupner G, Tzukerman M, Sakamoto B, Karin M, Pfahl M (1991) Antagonism between retinoic acid receptors and AP-1: implications for tumor promotion and inflammation. New Biol 3:1206-1219
36. Teyssier C, Belguise K, Galtier F, Chalbos D (2001) Characterization of the physical interaction between estrogen receptor alpha and JUN proteins. J Biol Chem 276:36361-36369
37. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, Kushner PJ (1999) The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 13:1672-1685
38. Lee SK, Kim HJ, Na SY, Kim TS, Choi HS, Im SY, Lee JW (1998) Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. J Biol Chem 273:16651-16654
39. Jakacka M, Ito M, Weiss J, Chien PY, Gehm BD, Jameson JL (2001) Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem 276:13615-13621
40. Lamb J, Ladha MH, McMahon C, Sutherland RL, Ewen ME (2000) Regulation of the Functional Interaction between Cyclin D1and the Estrogen Receptor. Mol Cell Biol 20:8667-8675
41. Awasthi S, Daverey A, Dwivedi A (2007) Modulation of AP-1 mediated estrogenic response by ormeloxifene in rat uterus. J Steroid Biochem Mol Biol 104:208-214
42. Milde-Langosch K, Kappes H, Riethdorf S, Löning T, Bamberger AM (2003) FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas. Breast Cancer Res Treat 77:265-275
43. Heximer SP, Cristillo AD, Russell L, Forsdyke DR (1996) Sequence analysis and expression in cultured lymphocytes of the human FOSB gene (GOS3). DNA Cell Biol 15:1025-1038
44. Karin M, Liu Z-G, Zandi E (1997) AP-1 function and regulation. Curr Opin Cell Biol 9:240-246
45. Ransone LJ, Visvader J, Lamph WW, Sassone-Corsi P, Verma IM (1989) Fos and Jun interaction: the role of the leucine zipper. Int J Cancer 4:10-21
46. Milde-Langosch K, Janke S, Wagner I, Schroder C, Streichert T, Bamberger AM, Janicke F, Loning T (2008) Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility. Breast Cancer Res Treat 107:337-347
47. Verdier-Sevrain S, Yaar M, Cantatore J, Traish A, Gilchrest BA (2004) Estradiol induces proliferation of keratinocytes via a receptor mediated mechanism. FASEB J 18:1252-1254
48. Stender JD, Frasor J, Komm B, Chang KC, Kraus WL, Katzenellenbogen BS (2007) Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol 21:2112-2123
49. Wang A, Schneider-Broussard R, Kumar AP, MacLeod MC, Johnson DG (2000) Regulation of BRCA1 expression by the Rb-E2F pathway. J Biol Chem 275:4532-4536
50. Perillo B, Sasso A, Abbondanza C, Palumbo G (2000) 17b-Estradiol Inhibits Apoptosis in MCF-7 Cells, Inducing bcl-2 Expression via Two Estrogen-Responsive Elements in the Coding Sequence. Mol Cell Biol 20:2890-2901